An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Category Primary study
Registry of
Year 2001
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
Epistemonikos ID: 5eeb9d74462801c4bd906f813ac952651237a783
First added on: Jun 26, 2015